Title: Piperine promotes autophagy flux by P2RX4 activation in SNCA/α-synuclein-induced Parkinson disease model - PubMed URL Source: https://pubmed.ncbi.nlm.nih.gov/34092198/ Markdown Content: ## Piperine promotes autophagy flux by P2RX4 activation in _SNCA_/α-synuclein-induced Parkinson disease model Ruolin Li et al. Autophagy.2022 Mar. ## Abstract Olfactory dysfunction, one of the earliest non-motor symptoms of Parkinson disease (PD), is accompanied by abnormal deposition of SNCA/α-synuclein in the olfactory bulb (OB). The macroautophagy/autophagy-lysosome pathway (ALP) plays an important role in degrading pathological SNCA and modulating this pathway may be a promising treatment strategy. P2RX4 (purinergic receptor P2X, ligand-gated ion channel 4), a member of the purinergic receptor X family, is a key molecule regulating ALP. Piperine (PIP) is a Chinese medicine with anti-inflammatory and anti-oxidant effects. The present study investigated the neuroprotective effects of PIP on SNCA overexpression-induced PD cell and mouse models. We found that PIP oral administration (25, 50 and 100 mg/kg) for 6 weeks attenuated olfactory deficits and delayed motor deficits in Thy 1-_SNCA_ transgenic mice overexpressing human _SNCA_. This was accompanied by a degradation of pathological SNCA in OB. In addition, PIP improved cell viability and promoted degradation of human SNCA in SK-N-SH cells. These protective effects were exerted via autophagy flux promotion by enhancing autophagosome-lysosome membrane fusion. Furthermore, tandem mass tag proteomics analyses showed that P2RX4 plays an important role in PIP treatment-induced activation of autophagy flux. These findings demonstrate that PIP exerts neuroprotective effects in PD models via promotion of autophagy flux and may be an effective agent for PD treatment.**Abbreviations:** 6-OHDA, 6-hydroxydopamine; ALP, autophagy-lysosome pathway; BafA 1, bafilomycin A 1; CoQ10, coenzyme Q10; DMSO: dimethyl sulfoxide; HPLC, high-performance liquid chromatography; IVE, ivermectin; LDH, lactate dehydrogenase; MAP1LC3/LC3-II, lipid-conjugated microtubule-associated protein 1 light chain 3; MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; mRFP-GFP, tandem monomeric red fluorescent protein-green fluorescent protein; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; OB, olfactory bulb; P2RX4, purinergic receptor P2X, ligand-gated ion channel 4; PD, Parkinson disease; PBS: phosphate-buffered saline; PI: propidium iodide; PIP, piperine; PLG, piperlongumine; p-SNCA, SNCA phosphorylated at Ser129; Rap, rapamycin; RT-PCR: quantitative real-time PCR; SNARE, soluble N-ethylmaleimide-sensitive factor-attachment protein receptor; SNCA/α-synuclein, synuclein, alpha; STX17, syntaxin17; TG, transgenic; TH, tyrosine hydroxylase; UPS, ubiquitin-proteasome system; WT, wild-type. **Keywords:** Parkinson disease; autophagy flux; piperine; tandem mass tag proteomics; Α-synuclein. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Conflict of interest statement The authors declare that they have no competing interests. ## Figures [![Image 1: Figure 1.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/206df9994951/KAUP_A_1937897_F0001_OC.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/33404f62f259/KAUP_A_1937897_F0001_OC.jpg) **Figure 1.** PIP attenuates olfactory dysfunction in _SNCA_ transgenic mice. (A) Male TG mice were orally treated with PIP (25, 50 and 100 mg/kg) or CoQ10 (200 mg/kg) for 6 weeks. (B–G) Buried food pellet (B), surface pellet (C), sucrose preference (D) and open field (E–G) tests were used to assess olfactory function. Data are expressed as means ± SEM (one-way analysis of variance). ##_P_<0.01, ###_P_<0.001, ####_P_<0.0001 _vs_. WT; ****_P_<0.0001 _vs_. TG (n=10–19). (H) The buried food pellet test was used to assess olfactory function with age. Data are expressed as means ± SEM (two-way analysis of variance). *_P_<0.05, **_P_<0.01, ****_P_<0.0001 (n=5–10). [![Image 2: Figure 2.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/0daeaa499ee2/KAUP_A_1937897_F0002_OC.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/776d271c29a1/KAUP_A_1937897_F0002_OC.jpg) **Figure 2.** PIP delays motor deficits and abrogates dopamine reduction in _SNCA_ transgenic mice. Male TG mice were orally treated with PIP (100 mg/kg) until 12-months-old. (A–B) Rotarod (A) and pole (B) tests were used to assess motor function. Data are expressed as means ± SEM (two-way analysis of variance). ***_P_<0.001, ****_P_<0.0001 (n=5–10). (C) TH (tyrosine hydroxylase) expression in the striatum and SN was assessed by immunohistochemistry. Scale bar: 500 µm. (D–E) Quantitative analysis of TH-positive neurons in the striatum (D) and SN (E). (F) Dopamine (DA) content in the striatum was assessed by HPLC. Data are expressed as means ± SD (one-way analysis of variance). ###_P_<0.001, ####_P_<0.0001 _vs_. WT; **_P_<0.01, ***_P_<0.001 _vs_. TG (n=3). [![Image 3: Figure 3.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/64444a8dcbff/KAUP_A_1937897_F0003_OC.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/e38c9caaf57a/KAUP_A_1937897_F0003_OC.jpg) **Figure 3.** PIP promotes the degradation of pathological SNCA in the OB of _SNCA_ transgenic mice. (A) Immunoblot results of Hs-SNCA levels in the RIPA soluble and insoluble fractions from OB. (B–C) Quantitative analysis of Hs-SNCA level in the RIPA soluble (B) and insoluble fractions (C) level in OB. ACTB was used as a loading control. The normalized ratio for the TG group was taken as 1. (D) Representative immunofluorescence images from mice slices of OB treated with and without PK. Scale bar: 75 µm, zoom scale bar: 10 µm. (E) _Hs-SNCA_ mRNA expression after PIP treatment was assessed by RT-PCR. Data are expressed as means ± SD (one-way analysis of variance). **_P_<0.01, ***_P_<0.001, ****_P_<0.0001 _vs_. TG (n=3). [![Image 4: Figure 4.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/835988eb1352/KAUP_A_1937897_F0004_OC.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/437e62dedfd6/KAUP_A_1937897_F0004_OC.jpg) **Figure 4.** PIP improves cell viability and reduces cytotoxicity by SNCA degradation. (A–D) Optimal PIP treatment concentration (A and B) and time (C and D) were determined in SK-N-SH cells by evaluating cell viability and cytotoxicity with the MTT and LDH assays, respectively. The normalized ratio for the con group was taken as 1. (E) Apoptotic SK-N-SH cells were identified by PI (red) and Hoechst (blue) staining. Scale bar: 50 µm. (F-G) Cell death rates (F) and SNCA-transfected neurons (G) were quantified in SK-N-SH cells. The normalized ratio for the con group was taken as 1. (H) Immunoblot results of Hs-SNCA level in SK-N-SH cells. (I) Quantitative analysis of Hs-SNCA level in SK-N-SH cells. ACTB was used as a loading control. The normalized ratio for the _SNCA_ group was taken as 1. (J) Representative immunofluorescence images showing SK-N-SH cells transfected with pmCherry-N1 or pmCherry-N1-_SNCA_ stained with the anti-phospho SNCA antibody. Scale bar: 10 µm. (K) _Hs-SNCA_ mRNA expression after PIP treatment in SK-N-SH cells was assessed by RT-PCR. Data are expressed as means ± SD (one-way analysis of variance). #_P_<0.05, ####_P_<0.0001 _vs_. con; *_P_<0.05, **_P_<0.01, ****_P_<0.0001 _vs. SNCA_ (n=3). [![Image 5: Figure 5.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/7c383daa2ee5/KAUP_A_1937897_F0005_OC.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/841a4be4acca/KAUP_A_1937897_F0005_OC.jpg) **Figure 5.** PIP promotes SNCA degradation via the ALP. (A) SK-N-SH cells were transfected with _SNCA_, and after 24 h, PIP was added at a concentration of 25 μM for 24 h. LC3-II and SQSTM1/p62 expression were elevated by western blotting in the presence of Rap (40 nM for 6 h) and BafA 1 (100 nM for 6 h). (B–C) Quantitative analysis of LC3-II (B) and SQSTM1/p62 (C) levels in SK-N-SH cells. The normalized ratio for the con group was taken as 1. #_P_<0.05, ####_P_<0.0001 _vs_. con; *_P_<0.05, **_P_<0.01, ***_P_<0.001, ****_P_<0.0001 _vs. SNCA_. (D) SK-N-SH cells were transfected with _SNCA_, and after 24 h, PIP was added at a concentration of 25 μM for 24 h. Hs-SNCA expression was elevated as shown by western blotting in the presence of BafA 1 (100 nM for 6 h). (E) Quantitative analysis of Hs-SNCA level in SK-N-SH cells. The normalized ratio for the _SNCA+_ BafA 1 group was taken as 1. Data are expressed as the means ± SD (one-way analysis of variance; n =3). (F) Autophagy flux was evaluated by counting autophagosome (RFP-GFP double positive puncta) and autolysosomes (RFP-single positive puncta) using mRFP-GFP-LC3 primary neurons. Scale bar: 10 µm. (G) The mean number of RFP and GFP dots were determined manually (n=10 cells). Data are expressed as the means ± SD (one-way analysis of variance; n =3). [![Image 6: Figure 6.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/a062950dc5f0/KAUP_A_1937897_F0006_OC.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/179017b0369f/KAUP_A_1937897_F0006_OC.jpg) **Figure 6.** TMT quantitative proteomic experiments show P2RX4 as an effective target for PIP-induced SNCA autophagic degradation. (A) Differential protein quantitative results of the mouse OB proteome in 6-months-old TG mice before and after 100 mg/kg PIP treatment compared to age-matched WT mice. _P <_ 0.05. (B) Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis shows that the ALP may be a potential target for PIP treatment. (C) TMT quantitative proteomic shows that P2RX4 is upregulated after PIP treatment in OB. (D) Western blotting validated the change in P2RX4. (E) Quantitative analysis of P2RX4 level in OB. The normalized ratio for the WT group was taken as 1. (F) Representative immunofluorescence images showing the colocalization of P2RX4 and LAMP1 (lysosome marker) from mice slices of OB. Scale bar: 10 µm. Data are expressed as means ± SD (one-way analysis of variance). #_P_<0.05 _vs_. WT; *_P_<0.05 _vs_. TG (n=3). [![Image 7: Figure 7.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/d47e4741e765/KAUP_A_1937897_F0007_OC.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/df3c813c9f56/KAUP_A_1937897_F0007_OC.jpg) **Figure 7.** PIP promotes SNCA autophagic degradation via P2RX4 activation. SK-N-SH cells were transfected with _SNCA_, and after 24 h, PIP was added at a concentration of 25 μM for 24 h. IVE (a positive allosteric effector of P2RX4; 10 μM for 24 h) served as a positive control, while 5-BDBD (a potent P2RX4 receptor antagonist; 5 μM for 24 h) served as a negative control. (A) Hs-SNCA, p-SNCA, LC3-II and SQSTM1/p62 levels were elevated by western blotting. (B–C) Quantitative analysis of Hs-SNCA (B) and p-SNCA (C) levels in SK-N-SH cells. The normalized ratio for the _SNCA_ group was taken as 1. (D–E) Quantitative analysis of LC3-II (D) and SQSTM1/p62 (E) levels in SK-N-SH cells. The normalized ratio for the con group was taken as 1. (F) Autophagy flux was evaluated by counting autophagosome (RFP-GFP double positive puncta) and autolysosomes (RFP-single positive puncta) in mRFP-GFP-LC3 primary neurons. Scale bar=10 µm. (G) The mean number of RFP and GFP dots were determined manually (n=10 cells). Data are expressed as means ± SD (one-way analysis of variance). ###_P_<0.001, ####_P_<0.0001 _vs_. con; *_P_<0.05, **_P_<0.01, ***_P_<0.001, ****_P_<0.0001 _vs. SNCA_; &_P_<0.05, &&&_P_<0.001, &&&&_P_<0.0001 _vs. SNCA_+PIP (n=3). [![Image 8: Figure 8.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/baa672771d17/KAUP_A_1937897_F0008_B.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/20068e543273/KAUP_A_1937897_F0008_B.jpg) **Figure 8.** PIP promotes autophagic flux by enhancing autophagosome-lysosome fusion via P2RX4 activation. (A) STX17 level was elevated as shown by western blotting in SK-N-SH cells. (B) Quantitative analysis of STX17 level in SK-N-SH cells. The normalized ratio for the con group was taken as 1. Data are expressed as means ± SD (one-way analysis of variance). #_P_<0.05 _vs_. con; *_P_<0.05 _vs. SNCA_; &_P_<0.05 _vs. SNCA_+PIP (n=3). (C) LC3-II, SQSTM1/p62 and STX17 levels were elevated as shown by western blotting of OB. (D–F) Quantitative analysis of LC3-II (D), SQSTM1/p62 (E) and STX17 (F) levels in OB. ACTB was used as a loading control. The normalized ratio for the WT group was taken as 1. Data are expressed as means ± SD (one-way analysis of variance). #_P_<0.05 _vs_. WT; *_P_<0.05 _vs_. TG (n=3). [![Image 9: Figure 9.](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/83070e20c726/KAUP_A_1937897_F0009_OC.gif)](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c12c/9037522/10a819f68067/KAUP_A_1937897_F0009_OC.jpg) **Figure 9.** PIP exerts neuroprotective effects against _SNCA_-induced injury by activating P2RX4 and promoting autophagy flux. SNCA inhibits autophagy flux by inhibiting STX17, which drives autophagosome-lysosome membrane fusion via P2RX4 inactivation. PIP restores P2RX4 activity and promotes autophagy flux, which resulted in pathological SNCA autophagic degradation. PIP: piperine. ## Similar articles * [Piperine promotes PI3K/AKT/mTOR-mediated gut-brain autophagy to degrade α-Synuclein in Parkinson's disease rats.](https://pubmed.ncbi.nlm.nih.gov/38158101/) Yu L, Hu X, Xu R, Zhao Y, Xiong L, Ai J, Wang X, Chen X, Ba Y, Xing Z, Guo C, Mi S, Wu X.Yu L, et al.J Ethnopharmacol. 2024 Mar 25;322:117628. doi: 10.1016/j.jep.2023.117628. Epub 2023 Dec 27.J Ethnopharmacol. 2024.PMID: 38158101 * [Piperine induces autophagy by enhancing protein phosphotase 2A activity in a rotenone-induced Parkinson's disease model.](https://pubmed.ncbi.nlm.nih.gov/27572322/) Liu J, Chen M, Wang X, Wang Y, Duan C, Gao G, Lu L, Wu X, Wang X, Yang H.Liu J, et al.Oncotarget. 2016 Sep 20;7(38):60823-60843. doi: 10.18632/oncotarget.11661.Oncotarget. 2016.PMID: 27572322 Free PMC article. * [Autophagy modulates SNCA/α-synuclein release, thereby generating a hostile microenvironment.](https://pubmed.ncbi.nlm.nih.gov/25484190/) Poehler AM, Xiang W, Spitzer P, May VE, Meixner H, Rockenstein E, Chutna O, Outeiro TF, Winkler J, Masliah E, Klucken J.Poehler AM, et al.Autophagy. 2014;10(12):2171-92. doi: 10.4161/auto.36436.Autophagy. 2014.PMID: 25484190 Free PMC article. * [Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.](https://pubmed.ncbi.nlm.nih.gov/23743292/) Perfeito R, Cunha-Oliveira T, Rego AC.Perfeito R, et al.Free Radic Biol Med. 2013 Sep;62:186-201. doi: 10.1016/j.freeradbiomed.2013.05.042. Epub 2013 Jun 3.Free Radic Biol Med. 2013.PMID: 23743292 Review. * [Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.](https://pubmed.ncbi.nlm.nih.gov/34729301/) Zhang K, Zhu S, Li J, Jiang T, Feng L, Pei J, Wang G, Ouyang L, Liu B.Zhang K, et al.Acta Pharm Sin B. 2021 Oct;11(10):3015-3034. doi: 10.1016/j.apsb.2021.02.016. Epub 2021 Feb 26.Acta Pharm Sin B. 2021.PMID: 34729301 Free PMC article.Review. ## Cited by * [Therapeutic and Neuroprotective Effects of Bushen Jianpi Decoction on a Rotenone-Induced Rat Model of Parkinson's Disease.](https://pubmed.ncbi.nlm.nih.gov/36437828/) Liang W, Yao L, Chen J, Chen Z, Wu X, Huang X.Liang W, et al.Evid Based Complement Alternat Med. 2022 Nov 18;2022:9191284. doi: 10.1155/2022/9191284. eCollection 2022.Evid Based Complement Alternat Med. 2022.PMID: 36437828 Free PMC article. * [Serine-129 phosphorylated _α_-synuclein drives mitochondrial dysfunction and calcium dysregulation in Parkinson's disease model.](https://pubmed.ncbi.nlm.nih.gov/40230488/) Jiao J, Liu W, Gao G, Yang H.Jiao J, et al.Front Aging Neurosci. 2025 Mar 31;17:1538166. doi: 10.3389/fnagi.2025.1538166. eCollection 2025.Front Aging Neurosci. 2025.PMID: 40230488 Free PMC article. * [Pathogenic Aspects and Therapeutic Avenues of Autophagy in Parkinson's Disease.](https://pubmed.ncbi.nlm.nih.gov/36831288/) Kinet R, Dehay B.Kinet R, et al.Cells. 2023 Feb 15;12(4):621. doi: 10.3390/cells12040621.Cells. 2023.PMID: 36831288 Free PMC article.Review. * [Paradigms and Success Stories of Natural Products in Drug Discovery Against Neurodegenerative Disorders (NDDs).](https://pubmed.ncbi.nlm.nih.gov/36606589/) Singh S, Chib S, Akhtar MJ, Kumar B, Chawla PA, Bhatia R.Singh S, et al.Curr Neuropharmacol. 2024;22(6):992-1015. doi: 10.2174/1570159X21666230105110834.Curr Neuropharmacol. 2024.PMID: 36606589 Free PMC article. * [Human Wild-Type α-Synuclein Drives Progressive Tau Pathology in a Disease-Relevant Mouse Model of Synucleinopathy.](https://pubmed.ncbi.nlm.nih.gov/41377958/) Senapati S, Sciortino A, Samples M, Shchankin N, Zhao Y, Montalbano M, Kayed R.Senapati S, et al.Res Sq [Preprint]. 2025 Dec 3:rs.3.rs-8166445. doi: 10.21203/rs.3.rs-8166445/v1.Res Sq. 2025.PMID: 41377958 Free PMC article.Preprint. ## References 1. 1. Kalia LV, Lang AE.. Parkinson’s disease. Lancet. 2015;386(9996):896–912. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/25904081/) 2. 1. Doty RL. Olfactory dysfunction in Parkinson disease. Nat Rev Neurol. 2012;8(6):329–339. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/22584158/) 3. 1. Breen KC, Drutyte G. Non-motor symptoms of Parkinson’s disease: the patient’s perspective. J Neural Transm. 2013;120(4):531–535. - [PMC](https://pmc.ncbi.nlm.nih.gov/articles/PMC3611030/) - [PubMed](https://pubmed.ncbi.nlm.nih.gov/23224635/) 4. 1. Jellinger KA. Neuropathobiology of non-motor symptoms in Parkinson disease. J Neural Transm. 2015;122(10):1429–1440. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/25976432/) 5. 1. Doty RL. Olfactory dysfunction in neurodegenerative diseases: is there a common pathological substrate? Lancet Neurol. 2017;16(6):478–488. - [PubMed](https://pubmed.ncbi.nlm.nih.gov/28504111/) ## Publication types * Actions ## MeSH terms * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions ## Substances * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions ## LinkOut - more resources * ### Full Text Sources * [Atypon](https://www.tandfonline.com/doi/10.1080/15548627.2021.1937897?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed) * [Europe PMC](https://europepmc.org/abstract/MED/34092198) * [PubMed Central](https://pmc.ncbi.nlm.nih.gov/articles/pmid/34092198/) * ### Other Literature Sources * [figshare - Access datasets and other research materials.](https://figshare.com/articles/by-resource-doi/10.1080/15548627.2021.1937897) * ### Medical * [MedlinePlus Health Information](https://medlineplus.gov/parkinsonsdisease.html) * ### Molecular Biology Databases * [Mouse Genome Informatics (MGI)](https://www.informatics.jax.org/reference/34092198) * ### Research Materials * [NCI CPTC Antibody Characterization Program](https://antibodies.cancer.gov/detail/CPTC-GSTP1-1) * ### Miscellaneous * [NCI CPTAC Assay Portal](https://assays.cancer.gov/non-CPTAC-3953)